Welcome to our dedicated page for Ainos SEC filings (Ticker: AIMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ainos, Inc. filings document operating results, material agreements, governance matters, and the securities structure of a Nasdaq-listed company with AIMD common stock and AIMDW warrants. Form 8-K reports cover annual and quarterly financial results, AI Nose commercialization updates, distribution rights for AINOS AI Nose products and services, and amendments to product-development and patent-use arrangements.
The company’s proxy materials disclose director elections, shareholder voting matters, compensation information, and governance procedures. Its filings also describe relationships involving Taiwan Carbon Nano Technology Corporation and Ainos KY, including control and voting-power matters relevant to the company’s corporate governance and development agreements.
Ainos, Inc. director Chiang Yao-Chung reported an open-market purchase of 2,000 shares of the company’s common stock at $2.13 per share. The shares are held indirectly through the director’s spouse, bringing indirect holdings to 7,779 shares. In addition, the director directly owns 90,880 shares of Ainos common stock as previously disclosed.
Ainos, Inc. director Chiang Yao-chung reported an open-market purchase of 250 shares of common stock at $2.30 per share on behalf of a spouse-held account. After this indirect transaction, that account holds 5,779 shares, while the director also directly owns 90,880 shares of Ainos common stock as previously disclosed.
Ainos, Inc. director Chiang Yao-chung reported an open-market purchase of 2,000 shares of common stock at $2.00 per share on May 27, 2026. The shares are held indirectly through his spouse, bringing indirect holdings to 5,529 shares. A footnote states he also directly owns 90,880 shares of Ainos common stock, indicating this trade is a modest increase to his overall position.
Ainos, Inc. director Lee Ting-Chuan reported an open-market sale of common stock. On May 26, 2026, the director sold 109,988 shares at $1.90 per share to cover income tax obligations, according to the footnote. After this transaction, the director directly holds 807,417 common shares.
Taiwan Carbon Nano Technology Corp, a ten percent owner of Ainos, Inc., reported an open-market sale of common stock. The entity sold 41,000 shares on May 26, 2026 at an average price of $2.36 per share and held 948,925 shares afterward.
According to a footnote, the shares were sold to cover income tax obligations, which makes this a more routine, tax-related transaction rather than a large change in ownership position.
Ainos, Inc. director Tsai Chun-Jung sold a total of 28,800 shares of Common Stock in open-market transactions. The sales occurred at prices of $1.55 and $1.87 per share. A footnote states the shares were sold to cover income tax obligations. After these transactions, Tsai directly holds 658,199 shares.
Ainos, Inc. director Lee Ting-Chuan sold a total of 18,302 shares of Common Stock in open-market transactions on May 21 and 22 at prices of $1.56 and $1.57 per share. A footnote explains that the sales were made to cover income tax obligations, and he continues to own 917,405 shares directly after these trades.
Ainos, Inc. director Chiang Yao-Chung reported two open-market purchases of the company’s common stock through indirect ownership by his spouse. On May 19, his spouse bought 2,200 shares at $1.68 per share, bringing that indirect position to 3,529 shares. On May 18, his spouse bought 500 shares at $1.65 per share, bringing that indirect position to 1,329 shares. A footnote states that, in addition to these indirect holdings, Chiang directly owns 90,880 shares of Ainos common stock.
Ainos, Inc. reported Q1 2026 results showing minimal revenue and continued losses while shoring up liquidity with new financing. Revenue was just $161, down sharply from $106,207 a year earlier as the company shifted AI Nose activity from healthcare-adjacent uses toward earlier-stage industrial deployments.
The net loss narrowed to $2,459,800 from $3,286,022, helped by a 30% reduction in operating expenses, especially lower share-based compensation and SG&A. Cash and cash equivalents rose to $2,841,422 from $417,353 at year-end, driven by a new related-party loan of about $2,812,940 and $601,600 of net proceeds from an at-the-market equity program.
Total liabilities increased to $16,389,637, including $11,000,000 of related-party convertible notes, while stockholders’ equity declined to $5,691,946. Management states that recurring losses, an accumulated deficit of $69,980,128, and dependence on future financings create “substantial doubt” about the company’s ability to continue as a going concern.
Ainos, Inc. reported first quarter 2026 results showing minimal revenue and a narrower loss as it advances its AI Nose commercialization strategy. Revenue for the quarter was $161, compared with $106,207 a year earlier, reflecting the shift toward infrastructure-focused AI Nose deployments still in early stages.
The company reported a net loss of $2.46 million, improving from a $3.29 million loss in the prior-year quarter, as operating expenses declined about 30% year-over-year to approximately $2.28 million. Cash and cash equivalents rose to $2.84 million from $0.42 million, supported by a previously announced NT$90 million (approximately $2.8 million) financing, while total liabilities increased to $16.39 million and stockholders’ equity decreased to $5.69 million.
Operationally, Ainos continued deploying AI Nose under a roughly three-year $2.1 million commercial arrangement in backend semiconductor manufacturing, initiated pilots in front-end semiconductor environments, expanded healthcare infrastructure pilots, and further developed its Smell ID datasets and Smell Language Model to support long-term Smell AI platform commercialization.